注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
上海君實生物科技有限公司是一家主要從事創新驅動生物製藥業務的中國公司。該公司主營業務為創新藥物的發現、臨床研究和開發。該公司的主要產品包括特立普珠單抗注射液、依替維單抗、阿達木單抗注射液等用於治療惡性腫瘤、自身免疫系統疾病、慢性代謝疾病、神經系統疾病和感染性疾病的藥物。該公司還從事重組人源化抗PCSK9單克隆抗體注射液等藥物的臨床研發。該公司主要為國內外市場提供產品。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jun Xiong | 48 | 2015 | Executive Chairman |
Cong Li | 60 | 2016 | Co-CEO & Executive Director |
Jianjun Zou | 52 | 2022 | GM, CEO & Executive Director |
Yi Tang | 56 | 2015 | Non-Executive Director |
Zhi Qian | 56 | 2018 | Independent Non-Executive Director |
Hui Feng | 48 | 2015 | Non-Executive Director |
Roy Steven Herbst | 61 | 2018 | Independent Non-Executive Director |
Pingping Wang | 42 | 2018 | Non-Employee Representative Supervisor |
Sheng Yao | 49 | 2016 | Senior VP & Executive Director |
Zhuobing Zhang | 57 | 2016 | Deputy GM & Executive Director |
Gang Wang | 67 | 2019 | Deputy GM, Chief Quality Officer, Senior VP of Industry Affairs & Executive Director |
Yu Wu | 39 | 2018 | Chairman of the Board of Supervisors |
Ning Li | 63 | 2018 | Executive Vice-Chairman of the Board |
Chun Zhang | 67 | 2020 | Independent Non-Executive Director |
Yilian Huo | 33 | 2021 | Employee Representative Supervisor |
Anming Meng | 61 | 2023 | Independent Non-Executive Director |
Xiaoyuan Feng | 68 | 2021 | Independent Non-Executive Director |
Xin Li | 45 | 2023 | Executive Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核